As a potential biomarker of treatment response, ctDNA and utDNA analyses were performed before systemic therapy, at restaging, and for responders at the beginning of adjuvant nivolumab. ctDNA was ...

Learn how ctDNA/MRD testing guides gastroesophageal cancer care—patient counseling, coverage hurdles, and what rising ctDNA means before scans. In an interview with Targeted Oncology, Rutika Mehta, MD ...

New study signals ctDNA MRD clearance and 90% drops predict better gastroesophageal cancer outcomes, fueling calls for prospective trials. In an interview with Targeted Oncology, Rutika Mehta, MD, MPH ...

Serial circulating tumor DNA (ctDNA) testing showed limited clinical benefit in colorectal cancer (CRC) surveillance when frequent imaging is used. The study's retrospective design and small sample ...

Molecular recurrence signals preceded symptoms or imaging in all recurrences observed, indicating ctDNA may enable earlier intervention than conventional surveillance paradigms. Post-neoadjuvant ctDNA ...

ctDNA testing effectively stratifies Merkel cell carcinoma patients into high and low recurrence risk categories, influencing surveillance strategies. The study's cohorts revealed significant ...

The study analyzed 202 patients with stage IV solid tumors—spanning 24 different cancer types—treated with immune checkpoint inhibitors and other immunotherapies. Utilizing a personalized testing ...

SAN FRANCISCO -- Circulating tumor DNA (ctDNA) measurements showed promise for identifying patients with early colorectal cancer (CRC) most likely to benefit from adjuvant therapy, analyses of two ...

Of the patients who were initially ctDNA positive and received pembrolizumab, 85% had ctDNA clearance at 6 months. Using circulating tumor DNA (ctDNA) test results to guide adjuvant treatment with ...

A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their ...